Top Qs
Timeline
Chat
Perspective
Plitidepsin
Chemical compound From Wikipedia, the free encyclopedia
Remove ads
Plitidepsin, also known as dehydrodidemnin B and sold under the brand name Aplidin, is a chemical compound extracted from the ascidian Aplidium albicans.[3]
Remove ads
Medical uses
In Australia, plitidepsin, in combination with dexamethasone, is indicated for the treatment of people with relapsed and refractory multiple myeloma.[1][2][4]
Pharmacological activity
Plitidepsin exhibits antitumor, antiviral and immunosuppressive activities. It shows promise in shrinking tumors in pancreatic, stomach, bladder, and prostate cancers.[5][6]
Plitidepsin inhibits the human protein eEF1A which has potential interactions with multiple coronavirus proteins. Plitidepsin possesses antiviral activity against SARS-CoV-2 in vitro and in an in vivo mouse model.[7]
Society and culture
Legal status
In July 2003, plitidepsin was granted orphan drug status by the European Medicines Agency (EMA) for treating acute lymphoblastic leukemia.[8] In December 2017, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorization for the treatment of multiple myeloma.[9] After a re-examination of the opinion, the refusal of the marketing authorization was confirmed in March 2018.[9] The CHMP is of the opinion that the benefits of Aplidin do not outweigh its risks.[9] In October 2020, the General Court upheld PharmaMar's appeal and annulled the decision refusing marketing authorization for Aplidin, and the European Commission then returned the application for Aplidin to the EMA.[9][10] In July 2025, PharmaMar withdrew its application for a marketing authorization of Aplidin for the treatment of multiple myeloma.[9]
Plitidepsin was approved for medical used in Australia in December 2018.[2]
References
Further reading
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads